The DEA has just announced that the same manufacturer of the notorious fentanyl has produced a synthetic marijuana product they deem more medically valuable and safer than real cannabis.
The announcement was made a few weeks ago in the Federal Register by the DEA that the drug Syndros, a liquid form of synthetic THC, will be now classified as a schedule 2 controlled substance, which means it can be legally prescribed by doctors. Meanwhile, organic marijuana continues to be listed right alongside heroin among Schedule 1 controlled substances. This category is reserved for drugs that have “no currently accepted medical use” and “a high potential for abuse.” Other drugs that have proven time and time again to hold medicinal value seem to be stuck in this category as well, although some things are changing.
Syndros hitting the market soon
Because the FDA has cleared Syndros for approval, it will be hitting the market soon. Syndros is made by Insys Therapeutics, an Arizona-based pharmaceutical company that has been accused of using shady marketing practices to sell Subysys, a spray form of the extremely potent synthetic opioid fentynal, which has been approved by the FDA for treatment of pain from cancer. A few top Insys executives, such as John Kapoor, the company’s billionaire founder, have been arrested and charged with bribing doctors and defrauding insurance companies. Insys and its former leaders are also facing several lawsuits from states and individuals for allegedly triggering America’s opioid crisis — and now they are trying to take over good old homegrown pot.
Something to be wary of?
Kapoor has pleaded not guilty and denied any and all wrongdoing. After being arrested on October 26 of this year, he was released on $1 million bail.
New Insys President and CEO, Saeed Motahari, said in a statement earlier this year that the launch of Syndros is a “pivotal milestone” for the company. Syndros is quite similar to Marinol, another synthetic THC product that was previously approved by the FDA to treat anorexia caused by aids and cancer. THC is the main psychoactive component in marijuana; it’s what causes the user to feel high, and often increases appetite. If you’re like me, you might be asking the obvious question: If THC has medicinal benefits, why do we need to make a synthetic version of it in order to to treat people? And the answer, in my opinion, is clear: Because you can’t patent cannabis and capitalize on it.
Syndros was granted preliminary Scedule 2 status in March and was listed alongside Oxycontin, Percocet, cocaine, methamphetamine and other drugs also considered to hold some medicinal value but have a “high potential for abuse.”
This article was originally published by our friends at Collective Evolution